Revenue up at MannKind, but losses mount
Westlake Village-based biotech company MannKind saw a slight bump in revenue in the first quarter thanks to its product Afrezza, but net losses continued to climb. MannKind released its earnings after the markets closed on May 12. It ended the day down 8.6% and regained 0.25% on May 13, to close at $4.03. MannKind, which Read More →
Westlake Village BioPartners makes big bet on gene therapy with Capsida
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen planning apartments on its land in Thousand Oaks
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Arcutis shares down after earnings report
Westlake Village-based Arcutis Biotherapeutics suffered a net loss in the first quarter of fiscal year 2021, but continues to hold a strong financial position with $446.5 million in assets. According to earnings released May 4, Arcutis lost $36 million in the first quarter, or 76 cents per share, compared to a loss of $28 million, Read More →
Atara beats estimates with loss in Q1
Atara Biotherapeutics had a net loss of $78.2 million in the first quarter of fiscal year 2021, slightly higher compared than same quarter a year earlier, when the company had a loss of $73.5 million. Despite this, Atara, an immunotherapy biotech company based in South San Francisco with some of its major operations in Thousand Read More →
Fight over Ventura County COVID records headed to court
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Thousand Oaks biotech firm closes $140M funding round
Capsida Biotherapeutics, a biotechnology startup based in Thousand Oaks, announced April 29 that it is emerging from “stealth mode” with a $140 million funding round led by Westlake Village BioPartners and Versant Ventures. The Series A round includes $50 million from Westlake Village BioPartners, a venture capital firm in Thousand Oaks focused on biotech startups Read More →
